PATENT COOPER	RATION TREATY
From the INTERNATIONAL SEARCHING AUTHORITY	24
To:	PCT
Davies Collison Cave Level 15 1 Nicholson Street MELBOURNE VIC 3000	NOTIFICATION OF TRANSMITTAL OF THE INTERNATIONAL SEARCH REPORT AND THE WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY, OR THE DECLARATION
	(PCT Rule 44.1)
Ran dre 8.8.04	Date of mailing 8 JIJN 2004 (day/month/year)
Applicant's or agent's file reference 12430560-TDO	FOR FURTHER ACTION See paragraphs 1 and 4 below
International application No.	International filing date
PCT/AU2004/000389	(day/month/year 29 March 2004
Applicant PROSTATE DIAGNOSTICS PTY LTD et al	
have been established and are transmitted herewith. Filing of amendments and statement under Article 19: The applicant is entitled, if he so wishes, to amend the claim When? The time limit for filing such amendmen international search report. Where? Directly to the International Bureau of V 1211 Geneva 20, Switzerland, Facsimile For more detailed instructions, see the notes on the ac The applicant is hereby notified that no international search to that effect and the written opinion of the International Search to that effect and the written opinion of the International Search to the protest together with the decision thereon has been request to forward the texts of both the protest and the no decision has been made yet on the protest; the applicant wishes to avoid or postpone publication,	At sis normally two months from the date of transmittal of the WIPO, 34 chemin des Colombettes 2 No.: +41 22 740 14 35 companying sheet. report will be established and that the declaration under Article 17(2)(a) arching Authority are transmitted herewith. nal fee(s) under Rule 40.2, the applicant is notified that: In transmitted to the International Bureau together with the applicant's colorison thereon to the designated Offices.
The applicant may submit comments on an informal basis on the International Bureau. The International Bureau will send a copy preliminary examination report has been or is to be established. before the expiration of 30 months from the priority date. Within 19 months from the priority date, but only in respect of se examination must be filed if the applicant wishes to postpone the some Offices even later); otherwise, the applicant must, within 2 into the national phase before those designated Offices. In respect of other designated Offices, the time limit of 30 months.	of such comments to all designated Offices unless an international These comments would also be made available to the public but not
Name and mailing address of the ISA/AU	Authorized officer
AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA E-mail address: pct@ipaustralia.gov.au Facsimile No. (02) 6285 3929	JULIE GALE Telephone No. (02) 6283 2272

PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

At the standard Glass Common	FOR FURTHER	see Form PCT/ISA/220
Applicant's or agent's file reference	ACTION	as well as, where applicable, item 5 below.
12430560-TDO		(Year) (Earliest) Priority Date (day/month/year)
International application No.	International filing date (day/month	28 March 2003
PCT/AU2004/000389	29 March 2004	28 (4141011 2003
Applicant	DEDIX Y COD 1	
PROSTATE DIAGNOSTICS	PTY LTD et al	
This international search report has been prep Article 18. A copy is being transmitted to the	pared by this International Searching A International Bureau.	Authority and is transmitted to the applicant according to
This international search report consists of a		
	y of each prior art document cited in t	his report.
Basis of the report		
· ·		e basis of the international application in the language in which
a. With regard to the language, the inte	d under this item.	to basis of the international appropriate in the basis and the international appropriate in the basis and the basis are the basis of th
The international sear Authority (Rule 23.1)		anslation of the international application furnished to this
b. With regard to any nucleotide	and/or amino acid sequence disclose	d in the international application, see Box No. I.
2. X Certain claims were found un	searchable (See Box No. II).	
3. Unity of invention is lacking	See Box No. III)	
4. With regard to the title,		
the text is approved as submitte	ed by the applicant.	·
X the text has been established by	y this Authority to read as follows:	
"Diagnosis of advanced can	cer"	
9		
	•	· •
5. With regard to the abstract,	· .	
X the text is approved as submitted	ed by the applicant.	
the text has been established, a one month from the date of many	according to Rule 38.2(b), by this Autailing of this international search repo	hority as it appears in Box No. IV. The applicant may, within rt, submit comments to this Authority.
6. With regard to the drawings,		
a. the figure of the drawings to be pul	olished with the abstract is Figure No.	•
as suggested by the	applicant.	
as selected by this A	uthority, because the applicant failed	to suggest a figure.
as selected by this A	uthority, because this figure better ch	aracterizes the invention.
b. X none of the figures is to be pu	blished with the abstract.	

AND THE PROPERTY OF THE PARTY OF THE PROPERTY OF THE PARTY OF THE PART

International application No.

PCT/AU2004/000389

Claims Nos.: To 1-78	because they relate to subject matter not required to be searched by this Authority, namely: 2. X Claims Nos.: 76-78 because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically: Claim 78 is directed to a pharmaceutical composition which comprises an agent capable of modulating the level of inhibin. The agent is defined merely by a desired result. There are no features which actually define the agent itself. Thus the scope of this claim is unclear and so broad that it is highly likely that known agents (either synthetic or natural compounds) would be encompassed within its scope. The addition of a carrier or diluent does not confer any novel aspect on this claim. The use of such an agent (claims 76 and 77) is also not clearly defined as the agent itself is not defined.
because they relate to subject matter not required to be searched by this Authority, namely: X Claims Nos.: 76-78	because they relate to subject matter not required to be scarched by this Authority, namely: 2. X Claims Nos.: 76-78 because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically: Claim 78 is directed to a pharmaceutical composition which comprises an agent capable of modulating the level of inhibin. The agent is defined merely by a desired result. There are no features which actually define the agent itself. Thus the scope of this claim is unclear and so broad that it is highly likely that known agents (either synthetic or natural compounds) would be encompassed within its scope. The addition of a carrier or diluent does not confer any novel aspect on this claim. The use of such an agent (claims 76 and 77) is also not clearly defined as the agent itself is not defined. 3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a) Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)
Example 2. Claims Nos.: 76-78 because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically: Claim 78 is directed to a pharmaceutical composition which comprises an agent capable of modulating the level of inhibin. The agent is defined merely by a desired result. There are no features which actually define the agent itself. Thus the scope of this claim is unclear and so broad that it is highly likely that known agents (either synthetic or natural compounds) would be encompassed within its sope. The addition of a carrier or dilutent does not confer any novel aspect on this claim. The use of such an agent (claims 76 and 77) is also not clearly defined as the agent itself is not defined. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a) 30x No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet) This International Searching Authority found multiple inventions in this international application, as follows: As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee. As all searchable claims for which fees were timely paid by the applicant, this international search report covers only those claims for which fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:	 2. X Claims Nos.: 76-78 because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically: Claim 78 is directed to a pharmaceutical composition which comprises an agent capable of modulating the level of inhibin. The agent is defined merely by a desired result. There are no features which actually define the agent itself. Thus the scope of this claim is unclear and so broad that it is highly likely that known agents (either synthetic or natural compounds) would be encompassed within its scope. The addition of a carrier or diluent does not confer any novel aspect on this claim. The use of such an agent (claims 76 and 77) is also not clearly defined as the agent itself is not defined. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a) Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)
Example 2. Claims Nos.: 76-78 because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically: Claim 78 it directed to a pharmaceutical composition which comprises an agent capable of modulating the level of inhibits. The agent is defined merely by a desired result. There are no features which actually define the agent itself. Thus the scope of this claim is unclear and so broad that it is highly likely that known agents (either synthetic or natural compounds) would be encompassed within its sope. The addition of a carrier or dituent does not confer any novel aspect on this claim. The use of such an agent (claims 76 and 77) is also not clearly defined as the agent itself is not defined. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a) BOX No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet) This International Searching Authority found multiple inventions in this international application, as follows: As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee. No required additional fees were paid, specifically claims Nos.: No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:	 2. X Claims Nos.: 76-78 because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically: Claim 78 is directed to a pharmaceutical composition which comprises an agent capable of modulating the level of inhibin. The agent is defined merely by a desired result. There are no features which actually define the agent itself. Thus the scope of this claim is unclear and so broad that it is highly likely that known agents (either synthetic or natural compounds) would be encompassed within its scope. The addition of a carrier or diluent does not confer any novel aspect on this claim. The use of such an agent (claims 76 and 77) is also not clearly defined as the agent itself is not defined. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a) Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically: Claim 78 is directed to a pharmaceutical composition which comprises an agent capable of modulating the level of inhibin. The agent is defined merely by a desired result. There are no features which actually define the agent itself. Thus the scope of this claim is unclear and so broad that it is highly likely that known agents (either synthetic or natural compounds) would be encompassed within its scope. The addition of a carrier or difuent does not confer any novel aspect on this claim. The use of such an agent (claims 76 and 77) is also not clearly defined as the agent itself is not defined. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a) Box No. III Observations where unity of invention is tacking (Continuation of item 3 of first sheet) This International Searching Authority found multiple inventions in this international application, as follows: As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.: No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:	because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically: Claim 78 is directed to a pharmaceutical composition which comprises an agent capable of modulating the level of inhibin. The agent is defined merely by a desired result. There are no features which actually define the agent itself. Thus the scope of this claim is unclear and so broad that it is highly likely that known agents (either synthetic or natural compounds) would be encompassed within its scope. The addition of a carrier or diluent does not confer any novel aspect on this claim. The use of such an agent (claims 76 and 77) is also not clearly defined as the agent itself is not defined. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a) Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)
an extent that no meaningful international search can be carried out, specifically: Claim 78 is directed to a pharmaceutical composition which comprises an agent capable of modulating the level of inhibin. The agent is defined merely by a desired result. There are no features which actually define the agent itself. Thus the scope of this claim is unclear and so broad that it is highly likely that known agents (either synthetic or natural compounds) would be encompassed within its scope. The addition of a carrier of diluter does not confer any novel aspect on this claim. The use of such an agent (claims 76 and 77) is also not clearly defined as the agent itself is not defined. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a) Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet) This International Searching Authority found multiple inventions in this international application, as follows: As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.: No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:	an extent that no meaningful international search can be carried out, specifically: Claim 78 is directed to a pharmaceutical composition which comprises an agent capable of modulating the level of inhibin. The agent is defined merely by a desired result. There are no features which actually define the agent itself. Thus the scope of this claim is unclear and so broad that it is highly likely that known agents (either synthetic or natural compounds) would be encompassed within its scope. The addition of a carrier or diluent does not confer any novel aspect on this claim. The use of such an agent (claims 76 and 77) is also not clearly defined as the agent itself is not defined. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a) Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)
Claim 78 is directed to a pharmaceutical composition which comprises an agent capable of modulating the level of inhibits. The agent is defined merely by a desired result. There are no features which actually define the agent itself. Thus the scope of this claim is unclear and so broad that it is highly likely that known agents (either synthetic or natural compounds) would be encompassed within its scope. The addition of a carrier or diluent does not confer any novel aspect on this claim. The use of such an agent (claims 76 and 77) is also not clearly defined as the agent itself is not defined. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a) Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet) This International Searching Authority found multiple inventions in this international application, as follows: As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.: No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:	Claim 78 is directed to a pharmaceutical composition which comprises an agent capable of modulating the level of inhibin. The agent is defined merely by a desired result. There are no features which actually define the agent itself. Thus the scope of this claim is unclear and so broad that it is highly likely that known agents (either synthetic or natural compounds) would be encompassed within its scope. The addition of a carrier or diluent does not confer any novel aspect on this claim. The use of such an agent (claims 76 and 77) is also not clearly defined as the agent itself is not defined. 3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a) Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a) Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet) This International Searching Authority found multiple inventions in this international application, as follows: As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.: No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:	because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a) Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)
This International Searching Authority found multiple inventions in this international application, as follows: 1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims. 2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee. 3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.: 4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:	Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)
As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.: No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:	
As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.: No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:	
searchable claims. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.: No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:	
payment of any additional fee. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.: No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:	Searchable claims.
covers only those claims for which fees were paid, specifically claims Nos.: No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:	As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:	
Devotes Protest	4. No required additional scarch fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Provides Protect	
The additional search ices were accompanied by the applicant's process.	Remark on Protest
No protest accompanied the payment of additional search fees.	No protest accompanied the payment of additional search fees.

International application No. PCT/AU2004/000389

CLASSIFICATION OF SUBJECT MATTER A.

Int. Cl. 7: G01N 33/574, 33/74, 33/68; A61K 38/00, 39/00; C12Q 01/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) WPAT; JAPIO; CAPlus; Medline (inhibin; neoplasm; neoplastic cell; (cancer/carcinoma/adenocarcinoma); (detect*/diagnos*/monitor*/modulat*/regulat*)

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
· x	WO 1995/032431 A1 (OXFORD BROOKES UNIVERSITY) 30 November 1995 Whole document.	51-54
x	WO 1987/005702 A1 (BIOTECHNOLOGY AUSTRALIA Pty. Ltd.) 24 September 1987 Whole document.	51-54
	WO 2001/029079 A1 (PRINCE HENRY'S INSTITUTE OF MEDICAL RESEARCH) 26 April 2001	
X	Whole document.	51-54
	WO 1998/047526 A1 (MONASH UNIVERSITY) 29 October 1998	c
X	Whole document.	51-75

X | See patent family annex |X| Further documents are listed in the continuation of Box C

- Special categories of cited documents:
- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier application or patent but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- - document published prior to the international filing date but later than the priority date claimed
- later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken
- document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report 8 JUN 2004

Name and mailing address of the ISA/AU

4 June 2004

AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA

E-mail address: pct@ipaustralia.gov.au Facsimile No. (02) 6285 3929

Authorized officer

JULIE GALE

Telephone No: (02) 6283 2272

International application No.
PCT/AU2004/000389

On). DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Sheth, N.A. et al., (1984) Neoplasma, vol. 31(3), pp 315-321. "Circulating levels of inhibin in cancer". Whole document.	1-54
Robertson, D.M. et al., (2001) Molecular and Cellular Endocrinology, vol. 180, pp 79-86. "Development of an inhibin α subunit ELISA with broad specificity". Whole document.	51-54
Betteridge A. and Craven, R.P. (1991) Biology of Reproduction, vol. 45, pp 748-754 "A two-site enzyme-linked immunosorbent assay for inhibin". Whole document.	51-54
Frias, A. E. et al., (1999) Cancer, vol. 85(2), pp 465-471. "Preoperative serum level of inhibin A is an independent prognostic factor for the survival of postmenopausal women with epithelial ovarian carcinoma". Whole document.	1-54
Mellor, S. L. et al., (1998) Journal of Clinical Endocrinology and Metabolism, vol. 83(3), pp 969-975. "Loss of the expression and localization of inhibin α-subunit in high grade prostate cancer". Whole document.	51-54
Petraglia F. et al., (1998) Journal of Clinical Endocrinology and Metabolism, vol. 83(3), pp 1029-1032. "Inhibin B is the major form of inhibin/activin family secreted by granulosa cell tumors". Whole document.	1-54
Robertson, D.M. et al., (2002) Molecular and Cellular Endocrinology, vol. 191, pp 97-103. "Inhibin/activins as diagnostic markers for ovarian cancer". Whole document.	1-54
Dowling CR and Risbridger GP (2000) Endocrine-Related Cancer, vol 7, pp 243-256. "The role of inhibins and activins in prostate cancer pathogenesis". Whole document.	1-75
	Sheth, N.A. et al., (1984) Neoplasma, vol. 31(3), pp 315-321. "Circulating levels of inhibin in cancer". Whole document. Robertson, D.M. et al., (2001) Molecular and Cellular Endocrinology, vol. 180, pp 79-86. "Development of an inhibin α subunit ELISA with broad specificity". Whole document. Betteridge A. and Craven, R.P. (1991) Biology of Reproduction, vol. 45, pp 748-754 "A two-site enzyme-linked immunosorbent assay for inhibin". Whole document. Frias, A. E. et al., (1999) Cancer, vol. 85(2), pp 465-471. "Preoperative serum level of inhibin A is an independent prognostic factor for the survival of postmenopausal women with epithelial ovarian carcinoma". Whole document. Mellor, S. L. et al., (1998) Journal of Clinical Endocrinology and Metabolism, vol. 83(3), pp 969-975. "Loss of the expression and localization of inhibin α-subunit in high grade prostate cancer". Whole document. Petraglia F. et al., (1998) Journal of Clinical Endocrinology and Metabolism, vol. 83(3), pp 1029-1032. "Inhibin B is the major form of inhibin/activin family secreted by granulosa cell tumors". Whole document. Robertson, D.M. et al., (2002) Molecular and Cellular Endocrinology, vol. 191, pp 97-103. "Inhibin/activins as diagnostic markers for ovarian cancer". Whole document.

Information on patent family members

International application No.
PCT/AU2004/000389

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Docume Search Re			Pate	nt Family Member		
WO 95324	31 AU	25322/95	CA	2191061	EP	0763206
	FI	964657	US	5952182		
WO 87057	02 AU	-72036/87	EP	0260306	NZ	219609
	ZA	8701844				
WO 01290	79 AU	10078/01	CA	2387576	EP	1226166
	NZ	518320	US	2003162229		
WO 98475	26 AU	70151/98	EP	1011715		

Due to data integration issues this family listing may not include 10 digit Australian applications filed since May 2001.

END OF ANNEX